Bill Text: FL S7072 | 2024 | Regular Session | Comm Sub

NOTE: There are more recent revisions of this legislation. Read Latest Draft

---

Bill Title: Cancer Funding

Spectrum: Committee Bill

Status: (Passed) 2024-06-19 - Chapter No. 2024-247, companion bill(s) passed, see SB 7078 (Ch. 2024-248), CS/CS/CS/SB 1582 (Ch. 2024-246) [S7072 Detail]

Download: Florida-2024-S7072-Comm_Sub.html

---

       Florida Senate - 2024                             CS for SB 7072
       
       
        
       By the Committee on Fiscal Policy; and the Appropriations
       Committee on Health and Human Services
       
       
       
       
       594-03660-24                                          20247072c1
    1                        A bill to be entitled                      
    2         An act relating to cancer funding; amending s.
    3         381.915, F.S.; revising the purpose of the Casey
    4         DeSantis Cancer Research Program; revising duties of
    5         the Department of Health under the program; creating
    6         the Cancer Connect Collaborative, a council, within
    7         the department for a specified purpose; authorizing
    8         the collaborative to make certain recommendations on
    9         state policy relating to cancer research or treatment;
   10         providing for membership and meetings of the
   11         collaborative; requiring the collaborative to develop
   12         a long-range comprehensive plan for the program;
   13         requiring the collaborative to solicit input from
   14         certain stakeholders in the development of the plan;
   15         requiring the collaborative to submit the plan to the
   16         Governor and the Legislature by a specified date;
   17         specifying required components of the plan; requiring
   18         the department to provide administrative support and
   19         staff to the collaborative; requiring the
   20         collaborative to advise the department on the awarding
   21         of grants issued through the Cancer Innovation Fund;
   22         requiring the collaborative to review grant
   23         applications and make recommendations to the
   24         department for awarding grants upon the appropriation
   25         of funds to the fund; requiring the department to make
   26         the final grant allocation award; requiring the
   27         collaborative to prioritize certain applications for
   28         grant funding; revising the frequency with which the
   29         department, in conjunction with participating cancer
   30         centers, must submit a specified report to the Cancer
   31         Control and Research Advisory Council and the
   32         collaborative; requiring the department to submit the
   33         report, and any equivalent independent reports, to the
   34         Governor and the Legislature by a specified date each
   35         year; revising requirements of such reports; beginning
   36         on a specified date, requiring that each allocation
   37         agreement issued by the department relating to certain
   38         cancer center payments include specified elements;
   39         providing an effective date.
   40          
   41  Be It Enacted by the Legislature of the State of Florida:
   42  
   43         Section 1. Present subsections (8), (9), and (10) of
   44  section 381.915, Florida Statutes, are redesignated as
   45  subsections (10), (12), and (13), new subsections (8) and (9)
   46  and subsection (11) are added to that section, and subsection
   47  (2) of that section is amended, to read:
   48         381.915 Casey DeSantis Cancer Research Program.—
   49         (2) The Casey DeSantis Cancer Research Program is
   50  established to enhance the quality and competitiveness of cancer
   51  care in this state, further a statewide biomedical research
   52  strategy directly responsive to the health needs of Florida’s
   53  citizens, and capitalize on the potential educational
   54  opportunities available to its students, and promote the
   55  provision of high-quality, innovative health care for persons
   56  undergoing cancer treatment in this state. The department shall:
   57         (a) Make payments to cancer centers recognized by the
   58  National Cancer Institute (NCI) at the National Institutes of
   59  Health as NCI-designated cancer centers or NCI-designated
   60  comprehensive cancer centers, and cancer centers working toward
   61  achieving NCI designation. The department shall distribute funds
   62  to participating cancer centers on a quarterly basis during each
   63  fiscal year for which an appropriation is made.
   64         (b) Make cancer innovation grant funding available through
   65  the Cancer Innovation Fund under subsection (9) to health care
   66  providers and facilities that demonstrate excellence in patient
   67  centered cancer treatment or research.
   68         (8) The Cancer Connect Collaborative, a council as defined
   69  in s. 20.03, is created within the department to advise the
   70  department and the Legislature on developing a holistic approach
   71  to the state’s efforts to fund cancer research, cancer
   72  facilities, and treatments for cancer patients. The
   73  collaborative may make recommendations on proposed legislation,
   74  proposed rules, best practices, data collection and reporting,
   75  issuance of grant funds, and other proposals for state policy
   76  relating to cancer research or treatment.
   77         (a) The Surgeon General shall serve as an ex officio,
   78  nonvoting member and shall serve as the chair.
   79         (b) The collaborative shall be composed of the following
   80  voting members, to be appointed by September 1, 2024:
   81         1. Two members appointed by the Governor, one member
   82  appointed by the President of the Senate, and one member
   83  appointed by the Speaker of the House of Representatives, based
   84  on the criteria of this subparagraph. The appointing officers
   85  shall make their appointments prioritizing members who have the
   86  following experience or expertise:
   87         a. The practice of a health care profession specializing in
   88  oncology clinical care or research;
   89         b. The development of preventive and therapeutic treatments
   90  to control cancer;
   91         c. The development of innovative research into the causes
   92  of cancer, the development of effective treatments for persons
   93  with cancer, or cures for cancer; or
   94         d. Management-level experience with a cancer center
   95  licensed under chapter 395.
   96         2. One member who is a resident of this state who can
   97  represent the interests of cancer patients in this state,
   98  appointed by the Governor.
   99         (c) The terms of appointees under paragraph (b) shall be
  100  for 2 years unless otherwise specified. However, to achieve
  101  staggered terms, the initial appointees under that paragraph
  102  shall serve 3 years for their first term. These appointees may
  103  be reappointed for no more than four consecutive terms.
  104         (d) Any vacancy occurring on the collaborative must be
  105  filled in the same manner as the original appointment. Any
  106  member who is appointed to fill a vacancy occurring because of
  107  death, resignation, or ineligibility for membership shall serve
  108  only for the unexpired term of the member’s predecessor.
  109         (e) Members whose terms have expired may continue to serve
  110  until replaced or reappointed, but for no more than 6 months
  111  after the expiration of their terms.
  112         (f) Members shall serve without compensation but are
  113  entitled to reimbursement for per diem and travel expenses
  114  pursuant to s. 112.061.
  115         (g) The collaborative shall meet as necessary, but at least
  116  quarterly, at the call of the chair. A majority of the members
  117  of the collaborative constitutes a quorum, and a meeting may not
  118  be held with less than a quorum present. In order to establish a
  119  quorum, the collaborative may conduct its meetings through
  120  teleconference or other electronic means. The affirmative vote
  121  of a majority of the members of the collaborative present is
  122  necessary for any official action by the collaborative.
  123         (h) The collaborative shall develop a long-range
  124  comprehensive plan for the Casey DeSantis Cancer Research
  125  Program. In the development of the plan, the collaborative must
  126  solicit input from cancer centers, research institutions,
  127  biomedical education institutions, hospitals, and medical
  128  providers. The collaborative shall submit the plan to the
  129  Governor, the President of the Senate, and the Speaker of the
  130  House of Representatives no later than December 1, 2024. The
  131  plan must include, but need not be limited to, all of the
  132  following components:
  133         1. Expansion of grant fund opportunities to include a
  134  broader pool of Florida-based cancer centers, research
  135  institutions, biomedical education institutions, hospitals, and
  136  medical providers to receive funding through the Cancer
  137  Innovation Fund.
  138         2. An evaluation to determine metrics that focus on patient
  139  outcomes, quality of care, and efficacy of treatment.
  140         3. A compilation of best practices relating to cancer
  141  research or treatment.
  142         (i) The department shall provide reasonable and necessary
  143  support staff and materials to assist the collaborative in the
  144  performance of its duties.
  145         (9) The collaborative shall advise the department on the
  146  awarding of grants issued through the Cancer Innovation Fund.
  147  During any fiscal year for which funds are appropriated to the
  148  fund, the collaborative shall review all submitted grant
  149  applications and make recommendations to the department for
  150  awarding grants to support innovative cancer research and
  151  treatment models, including emerging research and treatment
  152  trends and promising treatments that may serve as catalysts for
  153  further research and treatments. The department shall make the
  154  final grant allocation awards. The collaborative shall give
  155  priority to applications seeking to expand the reach of
  156  innovative cancer treatment models into underserved areas of
  157  this state.
  158         (10) Beginning July 1, 2025 2017, and each year every 3
  159  years thereafter, the department, in conjunction with
  160  participating cancer centers, shall submit a report to the
  161  Cancer Control and Research Advisory Council and the
  162  collaborative on specific metrics relating to cancer mortality
  163  and external funding for cancer-related research in this the
  164  state. If a cancer center does not endorse this report or
  165  produce an equivalent independent report, the cancer center is
  166  ineligible to receive shall be suspended from the program
  167  funding for 1 year. The department must submit this annual
  168  report, and any equivalent independent reports, to the Governor,
  169  the President of the Senate, and the Speaker of the House of
  170  Representatives no later than September 15 of each year the
  171  report or reports are submitted by the department. The report
  172  must include:
  173         (a) An analysis of trending age-adjusted cancer mortality
  174  rates in the state, which must include, at a minimum, overall
  175  age-adjusted mortality rates for cancer statewide and age
  176  adjusted mortality rates by age group, geographic region, and
  177  type of cancer, which must include, at a minimum:
  178         1. Lung cancer.
  179         2. Pancreatic cancer.
  180         3. Sarcoma.
  181         4. Melanoma.
  182         5. Leukemia and myelodysplastic syndromes.
  183         6. Brain cancer.
  184         7. Breast cancer.
  185         (b) Identification of trends in overall federal funding,
  186  broken down by institutional source, for cancer-related research
  187  in the state.
  188         (c) A list and narrative description of collaborative
  189  grants and interinstitutional collaboration among participating
  190  cancer centers, which may include grants received by
  191  participating cancer centers in collaboration, a comparison of
  192  such collaborative grants in proportion to the grant totals for
  193  each cancer center, a catalog of retreats and progress seed
  194  grants using state funds, and targets for collaboration in the
  195  future and reports on progress regarding such targets where
  196  appropriate.
  197         (11) Beginning July 1, 2024, each allocation agreement
  198  issued by the department relating to cancer center payments
  199  under subsection (2) must include all of the following:
  200         (a) A line-item budget narrative documenting the annual
  201  allocation of funds to a cancer center.
  202         (b) A cap on the annual award of 15 percent for
  203  administrative expenses.
  204         (c) A requirement for the cancer center to submit quarterly
  205  reports of all expenditures made by the cancer center with funds
  206  received through the Casey DeSantis Cancer Research Program.
  207         (d) A provision to allow the department and other state
  208  auditing bodies to audit all financial records, supporting
  209  documents, statistical records, and any other documents
  210  pertinent to the allocation agreement.
  211         (e) A provision requiring the annual reporting of outcome
  212  data and protocols used in achieving those outcomes.
  213         (12)(9) This section is subject to annual appropriation by
  214  the Legislature.
  215         (13)(10) The department may adopt rules to administer this
  216  section.
  217         Section 2. This act shall take effect July 1, 2024.